CHF 10073
Alternative Names: CHF-10073Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Chiesi Farmaceutici
- Class Antifibrinolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pulmonary fibrosis
Most Recent Events
- 13 Jan 2025 Phase-I clinical trials in Pulmonary fibrosis (In volunteers) in Belgium (Inhalation) (NCT06746064, EudraCT2024-515442-17-00)
- 24 Dec 2024 Chiesi Farmaceutici plans phase I trial in Pulmonary fibrosis (In Volunteers) in Belgium in January 2025 (NCT06746064)
- 24 Dec 2024 Preclinical trials in Pulmonary fibrosis in Italy (unspecified route), before December 2024